Interleukin 4

News and Video Search Results

News coverage

Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine

GlobeNewswire 20 May 2024

*NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and..

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
GlobeNewswire 20 May 2024
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
Accesswire 20 May 2024
Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting
GlobeNewswire 15 May 2024
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
Accesswire 14 May 2024

0 shares 1 views

You might like

Interleukin 4 media coverage

Infectious disease specialist in Palm Beach County outlines what's working in fight against COVID-19

Infectious disease specialist in Palm Beach County outlines what's working in fight against COVID-19

WPTV News | West Palm Beach 01 Apr 2020

While there is no cure for the coronavirus, doctors are seeing some encouraging results as they look for the best treatments to..

IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 13 May 2024
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire 13 May 2024
Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting
GlobeNewswire 13 May 2024
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
GlobeNewswire 13 May 2024